STOCKSCOPE

Legacy Minerals (ASX: LGM) Expands Mt Carrington to 1.6Moz as Bigger Gold-Silver Mine Plan Takes Shape

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:28 Oct 2026
Legacy Minerals (ASX: LGM) Expands Mt Carrington to 1.6Moz as Bigger Gold-Silver Mine Plan Takes Shape

Legacy Minerals Holdings (ASX: LGM) is reassessing the development potential of its Mt Carrington Gold-Silver Project in New South Wales after a substantial resource upgrade opened the door to a larger mining operation.

The September 2026 decision to optimise its Scoping Study follows a 39% increase in resource tonnage and improved geological confidence.

With preliminary project economics already indicating considerable value, the central question is whether a larger processing operation can improve production and cash flow without creating disproportionate capital requirements.

Key numbers

  • 1.6 million ounces: Updated Mt Carrington Mineral Resource expressed as gold equivalent.
  • 47.9 million tonnes: Total Mineral Resource grading approximately 1.0g/t gold equivalent.
  • $542 million: Modelled pre-tax net present value at a 7% discount rate under the May 2026 Scoping Study base case.
  • $220.5 million: Estimated initial development capital expenditure under the original study.
  • Approximately $6 million: Cash reserves at 30 June 2026, with no reported debt.

A larger resource changes Mt Carrington's development potential

Legacy's July 2026 resource upgrade substantially strengthened the geological foundations of its flagship project.

The updated estimate contains approximately 714,000 ounces of gold and 35 million ounces of silver, alongside copper, zinc and lead resources.

Compared with the previous estimate, total resource tonnage increased 39%, contained gold rose 9% and silver increased 44%.

Importantly, Indicated Resources expanded 69% to 19.3 million tonnes grading 1.22g/t gold equivalent.

This improvement provides greater confidence for mine planning and could support additional material being incorporated into future production schedules.

However, Mineral Resources are not Ore Reserves, and larger inventories do not automatically establish higher project profitability.

The financial opportunity depends on how efficiently Legacy can extract and process the additional material.

Could a larger processing plant improve the economics?

Legacy's May 2026 Scoping Study outlined a potential 19-year operation producing approximately 373,000 ounces of gold and 9.91 million ounces of silver.

The base case estimated $542 million in pre-tax net present value, a 32% internal rate of return and $1.25 billion in life-of-mine free cash flow.

These projections assumed a $220.5 million initial capital requirement and favourable long-term gold and silver prices.

However, the study predated the latest resource upgrade.

On 7 September, Legacy confirmed that engineering consultants Ausenco and WSP were assessing a larger processing operation than the previously considered one-million-tonne annual capacity.

The revised assessment is expected during the December 2026 quarter.

Increasing processing throughput could accelerate metal production and improve economies of scale.

Nevertheless, additional plant capacity would likely require higher upfront expenditure, making capital efficiency a crucial consideration.

Additional discoveries could extend the growth opportunity

Beyond Mt Carrington, Legacy continues investigating copper-gold opportunities at its Rockley Project.

On 22 September, the company identified three previously untested geophysical targets at Crystal Hill.

The priority Central target extends approximately 800 metres and produced chargeability responses reaching 45 millivolts per volt.

These results support further exploration, although geophysical anomalies do not establish mineral discoveries.

Legacy is also examining scandium potential at its NiCo Young Project.

While these opportunities provide portfolio diversification, Mt Carrington remains the clearest potential pathway towards future operating revenue.

Cash reserves support studies, not mine construction

Legacy's approximately $6 million cash position at 30 June 2026 provides funding flexibility for exploration and technical assessments.

However, the original $220.5 million development estimate demonstrates the substantial financing gap between completing studies and constructing a mine.

The company remains pre-production, with no established mining revenue or operating cash generation.

Future development could require debt, equity funding or strategic partnerships, introducing financing risk and potential shareholder dilution.

Conventional earnings multiples are therefore unsuitable for valuation.

A risk-adjusted assessment of project cash flows, financing requirements and development probability provides a more meaningful framework.

Insight: Mt Carrington's resource upgrade could reshape its production economics

What stands out to us is the relationship between Mt Carrington's 69% increase in Indicated Resources and Legacy's opportunity to reassess its processing capacity. The original $542 million pre-tax project valuation provides an encouraging starting point, but the expanded resource could support a materially different production profile. We believe the opportunity deserves attention if higher throughput improves annual cash generation without excessive additional capital expenditure. The next decisive test will be the optimised Scoping Study's revised production schedule, development costs and project returns.

The verdict: Bigger resources must deliver better economics

Legacy has strengthened Mt Carrington through resource growth, improved geological confidence and encouraging preliminary financial modelling.

The opportunity is substantial, but commercial viability remains dependent on further technical work and financing.

The optimised Scoping Study will determine whether the expanded resource can support stronger production economics and a credible pathway towards development.

For market participants, the critical question is whether increased processing capacity can generate sufficient additional cash flow to justify the capital required.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...